Search Results

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this probes for GPCR assays. GPCR, Celtarys will bring those lessons to the broader community, providing insight into assay development Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, , GPCR assay development , G protein-coupled receptors , GPCR podcast , Celtarys partnership Summary

David has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

His current work is mainly focused on screening and assay development to bridge the gap between in vitro

for receptor activator and continuously work to identify novel chemical modulators of AGPCRs through assay development and high-throughput screening efforts. I have previous work experience at two separate contract research organizations centered on assay development

Accelerated Program Progression: Design robust assay cascades and establish key go/no-go points to speed Define Actionable Objectives Together, we clarify specific, measurable goals, from target validation and assay development to CRO selection or portfolio strategy, ensuring a tailored approach. 3 Collaborative Execution Accelerated Preclinical Progression I streamline critical operational processes, from advanced assay Small missteps can derail entire programs: underperforming assays, off-track CROs, and data that fails

Stay informed with breaking news, important announcements, and key developments that matter to you. GPCR to support assay development worldwide. ✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr. 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds

During my PhD, I learnt radioligand binding assays, behavioral assays, autoradiography, stereotaxic surgeries nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Celtarys develops fluorescently labeled ligands designed for real-time, non-radioactive GPCR assays—enabling Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties GPCR Functional Assay Fluorescent GTPγS enables sensitive, non-radioactive GPCR activity assays for drug Custom Development Tailored fluorescent probes designed for unique research requirements.

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Howard Hughes Medical Institute appointment, Tom advanced a series of novel biochemical and biophysical assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

The conversation ended with Arthur's ongoing research and his development of a new operational model. Allosteric Modulation and Hybrid Molecules Arthur and Yamina discussed the development of an operational Arthur recounted a 2004 visit to a pharma company using replicates in assays. also discussed the potential of certain drugs, like flumazenil, as 'nails' or compounds that could be developed and Reproducibility Yamina and Arthur discussed the concept of a target product profile (TPP) in drug development

Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed I also invested a tremendous amount of time in developing my leadership skills.

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

Ilana Kotliar , his former graduate student, to explore the development of powerful multiplex tools designed Curiosity to Collaboration “We decided to evaluate the multiplexing methods... and found this Luminex assay ” – Tom Sakmar After exploring several screening techniques, the lab adopted the Luminex bead-based assay the Community “We have a library on Addgene... dual-epitope tagged GPCRs.” – Ilana Kotliar The team developed Keyword Cloud GPCR-RAMP interactions , multiplex assays , GPCR research community , Dr.

To address this, we developed the NTF release sensor (NRS), a genetically encoded reporter that facilitates latrophilin-type aGPCR Cirl/ADGRL in Drosophila, revealing NTF release and receptor dissociation within the developing Tobias Langenhan's group, where I currently manage a project to establish a drug screening assay for In addition, the platform was used to develop assays for high-throughput screening for challenging adhesion research aims to leverage this knowledge to identify novel pharmacological targets and contribute to the development

He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing original BRET and TR-FRET assays. loss-of-function variants of the MT2 melatonin receptors that are associated with type 2 diabetes (TD2) development

He is passionate about developing more rational ways to understand and engineer biology. technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay.

the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay Aside from his vast experience in drug development, not to mention his extensive publication record, We have a 90% discount for people who live and work in developing countries and a 15% discount for team

pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery.

pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery. a member of the lab, I am humbled to have been able to work with him and his team and use the tools developed

His journey highlights the transition from general drug development to a deep dive into G protein-coupled Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays mentorship, open communication, and peer learning — especially from undergraduate trainees — shape his development Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how Clements' work is primarily focused on translational developments of small molecule therapeutics, and

Prioritize assays based on project phase and decision points Map go/no-go logic that guides program momentum they’ll change outcomes No More Strategy Swirl I build structure that sticks—from CRO engagement to assay We have a 90% discount for people who live and work in developing countries and a 15% discount for team

clear expectations and deliverables to build trust and reduce delays • Align teams across roles—from assay Decisions—Not Delays I help turn great science into clear deliverables • Define program objectives and guide assay We have a 90% discount for people who live and work in developing countries and a 15% discount for team

Yamina will continue to develop and manage the Dr. Badr recounted Badr's Journey, Multiplexing Assays, and Collaboration Badr shared his learning process Yamina emphasized the potential of multiplexing assays in expanding the scope of scientific exploration understanding how Badr’s experiences influenced his current role, and Badr stressed the need for individuals to develop

She developed expertise over the past two decades studying structure/function relationships of GPCRs Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Driven by a passion for advancing drug development, John is committed to leveraging his expertise to research focuses on elucidating the molecular basis of membrane protein signalling using quantitative assays Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal

I employ a multidisciplinary approach that combines molecular pharmacology, biochemical assays, and biophysical GPCR Title: Development of a Transgenic Mouse Platform for the Detection of Endogenous G protein Activity

I study the cell and tissue level consequences of its failure in foetal development and of its reemployment were born at predicted Mendelian frequencies, appeared grossly indistinguishable from Con mice, and developed Since staring my postdoctoral training, I have continued to develop my expertise to answer fundamental and gene expression assays. Ligand-induced GPR110 signaling stimulates neurogenesis and synaptogenesis during development, and the

, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays

Work from our lab showed that the PCP components, including ADGRC2 and ADGRC3, are localized in the developing My research focus is the mechanisms of neural circuit development, function and disease." To exploit this expression profile, we have developed antibody-drug conjugates (ADCs) targeting CD97, We initially tested the ADC using in vitro WST-8 viability assays in human GBM cell lines and cell types oncogenesis in glioblastoma, the most common brain malignancy, and chromatin organization in human neural development

They also discussed the ongoing developments in the GPCR field, the upcoming adhesion GPCR consortium He explained that initially, the field lacked adequate tools, and his lab had to develop new techniques their understanding of the GPCRs through various approaches, including structural biology and signaling assays Yamina expressed her appreciation for Demet's work and asked about the development of the GPCR field GPCR Field and Naming Convention Discussion Demet and Yamina discussed the ongoing developments in the